AssayIndex

AX-2024-004269

GHRP-6 · 2 mg declared · ChinaPeptides Co., Ltd. (QYAOBIO) · lot QYB-2410-S5114

FAILVERIFIED
Report ID
AX-2024-004269
Compound
GHRP-6
Compound class
Growth-hormone axis peptides
Supplier
QYB — ChinaPeptides Co., Ltd. (QYAOBIO)
Batch / lot
QYB-2410-S5114
Declared label claim
2mg
Laboratory
Janoshik Analytical
Assay date
12 Dec 2024
Submitted
21 Dec 2024
Quarter
2024-Q4
Submitter
c.kuipers
Sample provenance
Supplier-supplied
Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

ParameterMethodResultUnitIndex spec
PurityRP-HPLC, 30 min gradient, 214 nm99.49% area≥ 99.0PASS
Total impuritiesRP-HPLC, sum of reported peaks0.51% area≤ 1.0PASS
Largest single impurityRP-HPLC — [D-Trp]-epimer0.37% area≤ 1.00PASS
Identity — theoretical monoisotopic masscalculated from molecular formula872.4446Da—NOT TESTED
Identity — observed monoisotopic massLC-MS, high resolution (ESI-TOF/QTOF)872.4429Da—NOT TESTED
Mass accuracyobserved vs theoretical-2.0ppm± 15PASS
Total peptide contentby difference from the gravimetric mass balance87.57%w/w—NOT TESTED
Target-compound contenttotal peptide content × purity87.12%w/w—NOT TESTED
Gross fill (as weighed)five-place balance, under nitrogen2.34mg2 mg declaredNOT TESTED
Recovered target peptidegross fill × target content2.039mg2 mg claimNOT TESTED
Recovery against label claimrecovered ÷ claim102.0%90.0 – 110.0PASS
Water contentKarl Fischer, coulometric, duplicate6.29%≤ 9.0PASS
Counter-ion (acetate)anion-exchange ion chromatography5.35%≤ 12.0PASS
Residual solvent + inorganic residueestimated — see /methods/residual-solvents-q3c/0.79%—NOT TESTED
Endotoxinkinetic chromogenic LAL7.46EU/mg≤ 5.0FAIL
Sterilitynot ordered on this submissionnot determined—no growthNOT TESTED
Appearancevisual, diffuse light, black and white backgroundWhite lyophilised cake, intact—white to off-white intact cakePASS
Reconstitution clarityreconstituted per submitter procedureClear, colourless, no visible particulates—clear, no visible particulatesPASS
pH (reconstituted, 1 mg/mL)potentiometric, two-point calibration6.14—2.5 – 8.0PASS
Retention time (observed)RP-HPLC, 30 min gradient8.38min8.44 ± 0.25 (normalised)PASS
Peak asymmetry (10 % height)Ph. Eur. 2.2.461.22—0.80 – 1.50PASS
Plate count, main peakN = 5.54 (t/w½)²70,262—≥ 20,000PASS
Resolution to nearest impurityvs [D-Trp]-epimer0.93—no index criterionREPORTED
Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

032826564984613128 GHRP-68.38 min · 99.49 % 8.26 same trace · ×100 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 70,262, and skew follows the reported asymmetry factor of 1.22. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.37 % impurity against a 99.49 % main peak is a line two pixels tall; the main peak runs off-scale there by design.
#PeakRTArea (µV·s)% areaΔ mass (Da)
1GHRP-6 — main peak8.384,835,52299.49—
2[D-Trp]-epimer8.2617,9830.370.000
3oxidised Trp (+16 Da)8.043,4020.07+15.995
4bis-oxidised Trp (+32 Da)7.801,9440.04+31.990
5des-Lys (−128 Da)8.161,4580.03-128.095
Closure check — purity + Σ impurities 100.00CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 872.4446 Da, computed from C46H56N12O6. All ppm figures on this site are against monoisotopic values — see why that matters.

0255075100375475575675775875975 [M+1H]1+873.45[M+2H]2+437.23 m/z Relative abundance (%)
Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 872.4429 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.
ChargeTheoretical m/zObserved m/zΔ m/zRel. abundance (%)
2+437.2296437.2287-0.000961.4
1+873.4519873.4502-0.0017100.0
Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

ComponentDetermination%w/w of cake
WaterKarl Fischer6.29
Counter-ion (acetate)ion chromatography5.35
Residual solvent + inorganic residueestimated0.79
Total peptide contentby difference87.57
Total100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

FigureSupplier COAThis reportIndex note
Purity (% area)99.8999.49divergence +0.38 pp vs batch median
Total impurities (% area)not stated0.51
Largest single impurity (% area)not stated0.37
Water (%)4.56.29
Counter-ion (%)not stated5.35
Peptide content (%w/w)not stated87.57
Endotoxin (EU/mg)5.277.46
Method stated on certificateYES—column, gradient and wavelength given
Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance
Supplier-supplied
Evidentiary weight
Weaker evidence. Read with the caveat below.
Chain of custody
Supplier despatch → laboratory direct (courier, cold pack, 12 d) → assay. Submitter did not handle the vial.
Assay date
12 Dec 2024
Submitted to the index
21 Dec 2024
Laboratory
Janoshik Analytical, Ostrava, Czechia
Method basis
30 min gradient · high-resolution MS
Verification status
VERIFIED
Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

lal_assay
7.46 EU/mg is above the index screening threshold of 5.0. Two things to keep separate: the index threshold is a screening figure, and a real limit is dose-dependent. The endotoxin dose-limit calculator does that arithmetic. What this record establishes is that the burden is measurable and high relative to the rest of the dataset.
scale_up_delta
Endotoxin determined but the LAL method is not stated. Kinetic chromogenic and gel-clot give different results and different sensitivity. The value cannot be interpreted without knowing which.
Contributor #C-8804
No endotoxin figure on this record, which is true of roughly three quarters of the index. It is the one measurement that cannot be inferred from any other and the one most often omitted.
underfill_3to1
7.46 EU/mg is at the sensitivity limit of Janoshik's LAL method. The true value is unspecified; treating this as a point estimate is overstating precision.
Section 7

Related records

Same batch — lot QYB-2410-S5114 n=7

ReportLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2024-004270QYB-2410-S5114Janoshik2024-Q499.536.18—Supplier-supplied1MARGINAL
AX-2024-004271QYB-2410-S5114Janoshik2024-Q499.516.4198.8Supplier-supplied1MARGINAL
AX-2024-004272QYB-2410-S5114Nordanalyt2024-Q499.425.83—Supplier-supplied1MARGINAL
AX-2024-004273QYB-2410-S5114Janoshik2024-Q499.855.9693.6Supplier-supplied1MARGINAL
AX-2024-004274QYB-2410-S5114PeptideMeter2024-Q499.935.8495.2Supplier-supplied2FAIL
AX-2024-004275QYB-2410-S5114Janoshik2024-Q499.486.06—Supplier-supplied2FAIL

Cross-sections

Other recent GHRP-6 records in the index.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042290HJHJ-2603-R2258Janoshik2026-Q399.713.05—Supplier-supplied2MARGINAL
AX-2026-042287HJHJ-2603-R2258VendorInvestigate2026-Q398.792.4390.9Buyer-sourced2FAIL
AX-2026-042288HJHJ-2603-R2258Kestrel2026-Q399.932.8292.8Supplier-supplied2MARGINAL
AX-2026-042289HJHJ-2603-R2258Janoshik2026-Q399.532.67104.7Supplier-supplied2MARGINAL
AX-2026-042291HJHJ-2603-R2258Janoshik2026-Q399.602.94101.3Supplier-supplied2MARGINAL
AX-2026-043560BCHBCH-2603-Y7018Janoshik2026-Q299.255.25—Supplier-supplied1MARGINAL
AX-2026-043564BCHBCH-2603-Y7018Medutest2026-Q298.444.83—Buyer-sourced1FAIL
AX-2026-043562BCHBCH-2603-Y7018PeptideMeter2026-Q298.574.5297.9Supplier-supplied1FAIL
Other recent QYB records in the index.
ReportCompoundLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041453RetatrutideQYB-2604-B5660VendorInvestigate2026-Q398.022.55—Buyer-sourced1MARGINAL
AX-2026-041454RetatrutideQYB-2604-B5660Janoshik2026-Q398.842.77—Supplier-supplied1MARGINAL
AX-2026-041538RetatrutideQYB-2602-G6308Medutest2026-Q398.502.85—Supplier-supplied2MARGINAL
AX-2026-041456RetatrutideQYB-2604-B5660Janoshik2026-Q398.233.24—Supplier-supplied1MARGINAL
AX-2026-041452RetatrutideQYB-2604-B5660Nordanalyt2026-Q398.503.36—Supplier-supplied1MARGINAL
AX-2026-041427IpamorelinQYB-2605-H4298Janoshik2026-Q399.934.12—Supplier-supplied0PASS
AX-2026-041488PT-141 (Bremelanotide)QYB-2607-L5615Janoshik2026-Q399.933.79—Supplier-supplied0PASS
AX-2026-041459RetatrutideQYB-2604-B5660VendorInvestigate2026-Q397.912.8492.2Buyer-sourced1MARGINAL